dapagliflozin
dapagliflozin: 14 clinical trials tracked.
dapagliflozin evidence translation
What we can confirm
14 tracked trials
What it means
What to watch
Prepared research question
What is verified about dapagliflozin, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence7 indications · 2 study sponsors
Clinical Trial Registry Records (14)showing 10 most recent
Dapagliflozin for Long COVID Syndrome
Primary endpoint: 6 month change in EQ-5D derived utility score.
A Phase III, Randomised, Double-blind, Study to Evaluate the Effect of Balcinrenone/Dapagliflozin Compared With Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Chronic Kidney Disease (Stage 3b and 4)
Primary endpoint: Time from randomization to first occurrence of cardiovascular death, death from kidney failure, kidney failure, sustained 50% or greater decline in eGFR, and heart failure event
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron and Dapagliflozin in Combination, Compared With Elecoglipron Alone and Dapagliflozin Alone, in Adults With Type 2 Diabetes Mellitus (Eluminate-5)
Primary endpoint: Change from baseline in Hemoglobin A1c (HbA1c)
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus (Eluminate-1)
Primary endpoint: Change from baseline in Hemoglobin A1c (HbA1c)
Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Persistent Albuminuria: A Randomized Controlled Clinical Trial
Primary endpoint: Albuminuria
An Open-Label Safety and Tolerability Pilot Study of Dapagliflozin in Stage IA Lung Adenocarcinoma
Primary endpoint: Incidence of adverse events
A Multicentre, Randomised, Double-blind, Active-Controlled, 2-arm Parallel-group Treatment, Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria
Primary endpoint: Change in log-transformed Urinary Albumin to Creatinine Ratio (UACR) from baseline
A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin Alone in Participants With Chronic Kidney Disease and High Proteinuria
Primary endpoint: Change in eGFR from baseline
SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes - a Randomized, Placebo Controlled, Multi-center Trial
Primary endpoint: Frequency of remission of hyperglycemia
Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes
Primary endpoint: Mean Systolic Blood Pressure